Imbio PHA (4.0.0) vs Imbio RV/LV Software
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your clinical practice requires a comprehensive assessment of cardiac structures from CTPA scans, including main pulmonary artery and aorta diameters, to aid in the diagnosis and risk stratification of both pulmonary embolism and hypertension. This tool is ideal for a broader evaluation of cardiopulmonary health, providing additional metrics beyond just ventricular ratios.
View Imbio PHA (4.0.0) →Choose Imbio RV/LV Software if…
Choose Imbio RV/LV Software if your primary focus is on rapid, automated measurement of right and left ventricular diameters and their ratio from CTPA scans, specifically for risk stratification in pulmonary embolism. This tool is best suited for workflows prioritizing a focused RV/LV assessment for quick clinical decision-making and seamless integration into various existing radiology platforms.
View Imbio RV/LV Software →Both Imbio PHA (4.0.0) and Imbio RV/LV Software are FDA-cleared, AI-powered tools designed to analyze CT pulmonary angiogram (CTPA) scans for cardiac structure measurements, aiding in the assessment of pulmonary conditions. The core functionality of both revolves around automatically measuring right and left ventricular diameters and calculating the RV/LV ratio. This shared capability is crucial for risk stratification in conditions such as pulmonary embolism. Both tools offer HIPAA compliance, generate annotated DICOM images, and provide summary PDF reports, integrating into existing radiology workflows.
The key practical difference lies in the scope of measurements. Imbio PHA (4.0.0) extends beyond RV/LV ratios to also measure main pulmonary artery and aorta diameters, subsequently calculating the PA/Ao ratio. This broader set of measurements provides a more comprehensive cardiac assessment. Therefore, a physician primarily focused on rapid right and left ventricular assessment for pulmonary embolism risk stratification might find Imbio RV/LV Software sufficient. However, for a physician seeking a more extensive cardiac evaluation from CTPA scans, including insights into potential pulmonary hypertension through PA/Ao ratios, Imbio PHA (4.0.0) would be the more appropriate choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Imbio RV/LV Software |
|---|---|---|
| Pricing | Contact for pricing | Subscription-based |
| Deployment | Cloud, Enterprise (on-premise), or via partners | Cloud-based (Imbio Cloud in AWS with Imbio Bridge), on-premise (Imbio Enterprise as a software-only VMware solution), or via partner platforms (e.g., Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools emphasize fully automated workflows and seamless integration with standard imaging environments like DICOM and PACS. Tool A highlights 'rapid, fully-automated assessment (typically in minutes),' while Tool B notes 'no user intervention required after scan completion,' indicating a very similar user experience focused on efficiency and automation.
Clinical Value
Imbio PHA (4.0.0)Tool A (Imbio PHA 4.0.0) offers a broader range of measurements, including right and left ventricle diameters, and main pulmonary artery and aorta diameters, calculating both RV/LV and PA/Ao ratios. In contrast, Tool B (Imbio RV/LV Software) focuses solely on the RV/LV ratio. This expanded measurement capability in Tool A provides more comprehensive clinical insights for diagnosing and risk stratifying both pulmonary embolism and hypertension.
Pricing & Value
Imbio RV/LV SoftwareTool B (Imbio RV/LV Software) offers greater transparency regarding its pricing model, explicitly stating it is 'subscription-based' and 'Based on number of analyses, number of installations.' Tool A (Imbio PHA 4.0.0) only provides 'contact for pricing,' which offers less upfront information for potential buyers.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant (third-party certified), and offering flexible deployment options including cloud, on-premise, and via partner platforms. While Tool B explicitly lists several partner platforms, Tool A also mentions deployment 'via partners,' suggesting comparable integration capabilities and foundational readiness for enterprise environments.
Innovation
Imbio PHA (4.0.0)Both tools utilize AI for automated measurements, but Tool A (Imbio PHA 4.0.0) shows a slightly more innovative approach by extending its AI capabilities to measure additional cardiac structures like the main pulmonary artery and aorta, and calculating the PA/Ao ratio. This broader application of AI within the same domain provides a more comprehensive set of diagnostic data points.
Support & Docs
TieAs both products are from the same company, Imbio, their general support and documentation resources are likely consistent across offerings. Imbio provides general support via phone and email, and user manuals are available upon request. There is no specific information provided in the structured facts or found via web search to differentiate the level or type of support and documentation between the two tools.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Imbio RV/LV Software |
|---|---|---|
| Name | Imbio PHA (4.0.0) | Imbio RV/LV Software |
| Description | Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Imbio RV/LV Software is an AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism. |
| Company | Imbio | Imbio |
| Key Features (Unique/Expanded) | Automated measurement of main pulmonary artery and aorta diameters; Calculates PA/Ao ratios; Rapid, fully-automated assessment (typically in minutes) | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Imbio RV/LV Software.